Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's executive management will deliver a corporate overview presentation on Tuesday, August 12, 2025, at 12:30 p.m. Eastern time.

Investors and interested parties can access the live audio webcast through Castle Biosciences' investor relations website at ir.castlebiosciences.com/events-presentations/. A replay of the presentation will be made available after the event.

Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. The award recognizes CEOs who demonstrate exceptional leadership, vision and values in Houston's leading organizations.

The recognition highlights Maetzold's leadership in building Castle Biosciences into a company focused on developing innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma. The company's CFO Frank Stokes praised Maetzold's nearly two-decade tenure for creating a patient-centered culture and driving meaningful progress in personalized disease insights.

Castle Biosciences (Nasdaq: CSTL) has achieved a significant regulatory milestone as its DecisionDx-Melanoma test received Breakthrough Device designation from the FDA. The test is a gene expression profile (GEP) test designed for patients with stage I-III cutaneous melanoma, providing personalized risk assessment for metastasis and sentinel lymph node positivity.

The designation, granted to devices offering improved treatment or diagnosis of life-threatening conditions, is expected to accelerate the development and review process. Castle Biosciences plans to submit a device marketing submission to the FDA, aiming to expand access to this diagnostic tool that guides risk-aligned management decisions for melanoma patients.

Castle Biosciences (Nasdaq: CSTL) has received multiple prestigious workplace awards in 2025, highlighting its strong corporate culture and employee satisfaction. The company earned its third consecutive national Healthcare Industry Top Workplaces award, ranking third in its size bracket, and a fourth consecutive Arizona Top Workplaces award.

Additionally, Castle secured five Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values. These recognitions are based on anonymous employee feedback collected through third-party surveys by Energage, demonstrating Castle's successful implementation of its people-first culture and commitment to employee satisfaction.

Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has scheduled its second quarter 2025 financial results release for Monday, August 4, 2025, after market close.

The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results. Investors can access the webcast through the company's website or direct link, with U.S. participants able to join via phone at 1-833-470-1428 using access code 638217. A Q&A session will follow management's presentation, and a replay will be available after the call.

Castle Biosciences (CSTL) announced that its Board of Directors' Compensation Committee has granted restricted stock units (RSUs) to 66 new employees on June 14, 2025. The RSU grants cover 135,978 shares of common stock and were issued under the Company's 2022 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs feature a four-year vesting schedule, with 25% vesting after the first year and the remaining shares vesting in three equal annual installments, contingent on continued employment.

Castle Biosciences (CSTL) has entered a strategic collaboration and license agreement with SciBase to develop diagnostic tests for dermatologic diseases using SciBase's Electrical Impedance Spectroscopy technology. The initial focus is on developing a test to predict flares in atopic dermatitis (AD) patients, targeting a potential U.S. market of 24 million patients. The collaboration divides territories with SciBase covering EU, Switzerland, UAE, Japan, and South Korea, while Castle operates in North America. The agreement includes revenue sharing with SciBase receiving single-digit royalties on Castle's gross margin, a low double-digit markup on product sales, and a $5 million milestone payment when Castle's annual sales reach $50 million. Development costs will be shared, with SciBase deferring initial clinical development costs for AD flare prediction, to be reimbursed from future royalties and milestone payments.

Castle Biosciences (CSTL) announced that CEO Derek Maetzold will participate in a panel discussion at the 2025 BIO International Convention in Boston from June 16-19. The panel, titled 'Advancing Innovative Risk-Stratification Tests That Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry,' will focus on challenges faced by precision medicine companies in commercializing diagnostic tests. The session will take place on June 17, 2025, from 11 a.m.-12 p.m. Eastern Time in Room 251. The panel will be moderated by Michael Ryan from McDermott Will & Emery and include industry experts Mara Aspinall from Illumina Ventures and Gillian Hooker from Concert. Castle Biosciences will also be represented at the City of Phoenix Pavilion (1639) and Texas Pavilion (2665).

Castle Biosciences (CSTL) will present new research at ASCO 2025 showcasing the effectiveness of their DecisionDx-Melanoma test in improving melanoma patient care. The study, involving over 13,500 patients, demonstrates that the test was associated with a 32% reduction in mortality risk compared to untested patients. The 31-gene expression profile test significantly stratified mortality risk within AJCC sub-stages, with Class 2B patients showing a hazard ratio of 4.59 and Class 1B/2A patients showing 3.42 (p<0.001). Additionally, Castle will present findings on a new 16-protein test for uveal melanoma, showing 91% sensitivity and 92% negative predictive value in distinguishing between low and high-risk uveal melanoma lesions through liquid biopsy.